Tags : Novel Antibody

M&A

Roche Acquires Tusk Therapeutics for $81. 24 M (€70M) for

Shots: Tusk to get an upfront $81.2M with contingent payments up to $678.9M (€ 585M) based on certain milestones Roche plans to continue the development of novel Ab developed by Tusk for depleting regulatory T-cells. The program is expected to hit the clinics by Q4’19 for cancer patients Tusk’s Spinout Black Belt Therapeutics, will hold […]Read More